NKTR
-
AstraZeneca and Nektar Ink Agreement for Constipation Drug
AstraZeneca and Nektar Therapeutics have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational product that is being evaluated for the treatment of opioid-induced constipatio…
NKTR | 24 September 2009
